Paediatrics Search
Paediatrics Paediatrics
mumps
MUMPS
Mumps is a self-limited viral disease characterized by nonsuppurative swelling and tenderness of one or both parotid glands.
It commonly affects the children aged 2-12 years and very uncommon in <1 year of age.
It is caused by a single-stranded RNA virus classified under Paramyxoviridae family or mumps virus.
Transmission is through airborne droplets from respiratory secretion of infected persons.
Incubation period is typically 14-21 days.

Patient Education

  • Advise parents to isolate the patient from large-population facilities (eg daycare center) until 9 days after the swelling begins or until the swelling subsides
  • Advise on good handwashing practices
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
How do doctors choose to prescribe NOACs vs VKAs for stroke prevention?
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Tenofovir disoproxil fumarate monotherapy improves virologic response in HBV patients
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Long-term use of benralizumab efficacious, safe for severe, uncontrolled asthma
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Antidiabetics charting new territory in renal preservation
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.